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Purpose: The genetic basis of primary angle closure glaucoma (PACG) has yet to be elucidated. Ocular characteristics
related to PACG such as short hyperopic eyes with shallow anterior chambers suggest the involvement of genes that
regulate ocular size. CHX10, a retinal homeobox gene associated with microphthalmia, and MFRP, the membrane-type
frizzled-related protein gene underlying recessive nanophthalmos, represent good candidate genes for PACG due to the
association with small eyes. To investigate the possible involvement of CHX10 and MFRP in PACG, we sequenced both
genes in PACG patients with small ocular dimensions.
Methods: One hundred and eight Chinese patients with axial lengths measuring 22.50 mm or less were selected for
analysis. Ninety-three age- and ethnically-matched control subjects were also screened. Genomic DNA was extracted
from leukocytes of peripheral blood samples, and the exons of CHX10 and MFRP were amplified by polymerase chain
reaction (PCR) and subjected to bidirectional sequencing and analysis.
Results: All study patients were Chinese with a mean age of 66.2±9.1 years (range 46–86). There were 77 females (71.3%).
Forty-nine out of the one hundred and eight subjects had previous symptomatic PACG, and 59 had asymptomatic PACG.
The mean axial length was 21.90±0.50 mm (range 19.98–22.50 mm). We identified a possible disease-causing variant in
CHX10 (c.728G>A) resulting in Gly243Asp substitution in one patient. This variant was not found in 215 normal controls.
Several CHX10 and MFRP polymorphisms were also identified.
Conclusions: Our results do not support a significant role for CHX10 or MFRP mutations in PACG.
Glaucoma, a group of heterogeneous optic neuropathies
characterized by progressive visual field loss, is the leading
cause of irreversible blindness worldwide [1-3]. Categorized
according to the anatomy of the anterior chamber angle, there
are  two  main  forms  of  glaucoma,  primary  open-angle
glaucoma  (POAG)  and  primary  angle  closure  glaucoma
(PACG). Primary angle closure glaucoma is a major form of
glaucoma in Asia, especially in populations of Chinese and
Mongoloid descent [4-9] compared to primary open-angle
glaucoma, which is the predominant glaucoma disease among
Caucasians and Africans [10,11]. PACG is responsible for
substantial blindness in Mongolia [6], Singapore [7], China
[8,9], and India [12,13]. It is estimated that PACG blinds more
people than POAG worldwide [8].
Glaucoma has a major genetic basis, estimated to account
for at least a third of all glaucoma cases [14-16]. Although
several genes have been identified for POAG [17-19], the
gene(s) underlying PACG is still unknown. Eyes with PACG
tend to share certain anatomic biometric characteristics. These
include a short axial length of the eyeball, shallow anterior
chamber depth, hyperopia, and a thicker and more anteriorly
positioned  lens  compared  to  the  rest  of  the  population
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[20-24].  The  association  with  smaller  ocular  dimensions
makes ocular developmental genes possible candidate genes
for  the  condition.  Eyes  with  microphthalmia  and
nanophthalmos are characterized by very short axial length,
high hypermetropia, high lens/eye volume ratio, and a high
prevalence of angle closure. Intraocular pressure is greatly
elevated in many cases. Recently, two “small eye” genes have
been  identified.  Non-syndromic  microphthalmia  was
associated  with  mutations  in  the  retinal  homeobox  gene
CHX10 [25,26]. Sundin et al. [27] found that null mutations in
MFRP  ,  which  encodes  a  Frizzled  related  protein  that
regulates  axial  length,  results  in  extreme  hyperopia,  and
nanophthalmos.
To investigate the possible involvement of CHX10 and
MFRP in PACG, we sequenced both genes in a sample of
PACG patients with small ocular dimensions.
METHODS
Patients:  Subjects  with  PACG  were  recruited  from  the
glaucoma service of the Singapore National Eye Centre and
National University Hospital (Singapore). Written informed
consent was obtained from all subjects, and the study had the
approval of the ethics committees of the two hospitals and was
performed  according  to  the  tenets  of  the  Declaration  of
Helsinki. Standardized inclusion criteria for PACG were used,
which were as follows:
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13131. The presence of glaucomatous optic neuropathy, which
was defined as disc excavation with loss of neuroretinal rim
tissue with a cup:disc ratio of 0.7 or greater when examined
with a 78D biomicroscopic lens.
2. Visual field loss detected with static automated white-
on-white threshold perimetry (program 24–2 SITA, model
750, Humphrey Instruments, Dublin, CA) that was consistent
with glaucomatous optic nerve damage. This was defined as
Glaucoma  Hemifield  test  outside  normal  limits  and/or  an
abnormal pattern standard deviation with p<0.05 occurring in
the normal population.
3. A closed angle on indentation gonioscopy. A closed
angle was defined as an angle of at least 180 degrees in which
the posterior pigmented trabecular meshwork was not visible
on gonioscopy.
4. We only included eyes with axial lengths less than
22.5 mm. Axial length measurements were performed by A-
mode applanation ultrasonography (Sonomed A2500, Haag-
Streit, Koniz, Switzerland).
Subjects were further categorized into two groups, those
who  presented  with  acute  symptomatic  angle-closure  and
those who had asymptomatic PACG. Characteristics of the
acute angle closure episode were obtained from the charts
retrospectively.  For  this  study,  acute  angle-closure  was
defined as follows:
1. Presence of at least two of the following symptoms:
ocular  or  periocular  pain,  nausea,  and/or  vomiting,  an
antecedent  history  of  intermittent  blurring  of  vision  with
haloes.
2. An intraocular pressure (IOP) of more than 28 mmHg
(as measured by Goldmann applanation tonometry) and the
presence of at least three of the following signs: conjunctival
injection,  corneal  epithelial  edema,  mid-dilated  unreactive
pupil,  shallow  anterior  chamber,  glaucomflecken,  and  iris
atrophy.
Ninety-three normal controls were screened in this study.
Normal  control  subjects  had  open  angles,  intraocular
pressures of less than 21 mmHg, axial lengths greater than
23 mm, normal optic nerve heads with cup:disc ratio of less
than or equal to 0.5, normal Heidelberg Retinal Tomography
scans, and no other ocular pathology or family history of
glaucoma.
Mutational  analysis:  Genomic  DNA  was  extracted  from
leukocytes of the peripheral blood samples, and exons of
CHX10  and  MFRP  were  amplified  by  polymerase  chain
reaction (PCR) with the DNA Theromocycler 9700 (Applied
Biosystems, Foster City, CA). PCR reactions were performed
in 50 µl reaction volumes containing 10 mM TrisHCl (pH 8.9),
50 mM KCl, 1.5 mM MgCl2, 25 pmoles of each primer, 200
μM of each dNTP, 50–100 ng of patient genomic DNA, and
0.7 units of Taq thermostable DNA polymerase (Promega,
Madison,  WI).  Cycling  parameters  were  3  min  at  95  °C
followed by 35 cycles of 30 s at 95 °C, 30 s at the melting
temperature (Tm) of the primers (52-62 °C), and 30 s at 72 °C
with a final 5 min extension at 72 °C. PCR products were
purified  using  GFX  PCR  clean  up  columns  (Amersham
Biosciences,  Piscataway,  NJ).  Sequence  variations  were
identified  by  automated  bidirectional  sequencing  using
BigDye terminator v3.1 chemistries (Applied Biosystems).
An automated DNA sequencer (Model, ABI PRISM 3100,
Applied  Biosystems)  was  used.  Primers  for  sequence
reactions were the same as those for the PCR reaction.
Statistical analysis was performed using the χ2/Fisher’s
Exact tests (SPSS 11.5).
RESULTS
A total of 108 subjects with PACG were studied of which 49
subjects presented with acute angle closure while 59 eyes had
asymptomatic PACG. All subjects were of Chinese ethnicity.
There were 77 females (71%), and the mean age was 66.2±9.1
years (range 46–86 years; Table 1).
Four  CHX10  sequence  alterations  consisting  of  two
heterozygous missense and two synonymous changes were
identified  in  our  study  subjects  (Table  2).  The  two
synonymous variations, Ser157Ser and Pro250Pro, were both
found in control subjects. The missense sequence alteration,
Asp291Asn (D291N), identified in seven PACG cases, was
also  detected  in  eight  normal  controls.  The  Gly243Asp
(728G>A) missense change was found in one patient with
previous acute PACG (who also had the Arg257His mutation
in MFRP, see below) but not in a total of 215 controls of
Chinese ethnicity (Figure 1A). We analyzed an additional 122
control subjects for this particular sequence variant apart from
the  initial  93  control  subjects  enrolled  in  the  study.  The
Gly243Asp  (728G>A)  missense  change  also  involved  a
residue that is conserved across several species (Figure 1B).
The patient concerned was an 82-year-old lady with chronic
PACG first diagnosed at age 75. At presentation, the vertical
cup:disc ratio was 0.8 in both eyes, and gonioscopy revealed
360  degrees  of  closed  angles  with  extensive  peripheral
anterior  synechiae.  The  axial  length  was  21.05  mm,  and
anterior chamber depth was 2.09 mm in the affected eye.
Two  missense  changes  (Val136Met  and  Arg257His)
were identified in MFRP. The Arg257His variation (Figure
2A) that was identified in only two PACG cases was not
detected in 93 controls. In homologous sequences, histidine
residue is also seen in place of the arginine residue (Figure
2B). One of the patients with the Arg257His change in MFRP
also  had  the  rare  Gly243Asp  variation  in  CHX10.  Four
common  silent  MFRP  variations  were  also  identified
(Arg64Arg, Tyr164Tyr, His180His, and Leu318Leu). The
distribution of these variants between PACG and controls was
not statistically significant.
DISCUSSION
There  are  few  studies  to  date  on  the  genetics  of  PACG,
although transmission via a single, dominant gene has been
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on PACG that suggest a genetic basis for the condition. First,
ocular characteristics related to angle closure glaucoma are
more common in close relatives of affected patients than in
the  general  population;  these  characteristics  include  short
Figure 1. The c.728G>A (Gly243Asp) variation in CHX10. A: The
wild type sequence is shown on the left to compare with the variant
CHX10 sequence on the right. The comparison depicts the G>A
transition that changed codon 243 from glycine (GGC) in the wild
type sequence to aspartic acid (GAC) in the variant CHX10 sequence.
B: Protein alignment of human (Homo sapiens) CHX10 (residues
215-261)  is  compared  to  other  CHX10-like  proteins  from  other
species,  i.e.,  chimp  (P.  troglodytes),  mouse  (M.  musculus),  rat
(R.norvegicus), chick (G. gallus), puffer fish (T. nigroviridis), and
worm (C. elegans). This comparison shows the conservation of the
glycine 243 residue in CHX10.
axial lengths of the eyeball and shallow anterior chambers
[29-33]. First-degree relatives of subjects with PACG have a
Figure 2. The c.770G>A (Arg257His) variation in MFRP. A: The
wild type sequence is shown on the left to compare with the variant
MFRP sequence on the right. The comparison depicts the G>A
transition that changed codon 257 from arginine (CGC) in the wild
type sequence to histidine (CAC) in the variant MFRP sequence. B:
Protein alignment of human (H. sapiens) MFRP (residues 242-273)
is compared to other MFRP-like Proteins from other species, i.e.,
cow (B. taurus), mouse (M. musculus), rat (R. norvegicus), fugu (T.
rubripes), puffer fish (T. nigroviridis), and Xenopus (X. tropicalis).
This comparison shows the conservation of the arginine 257 residue
of MFRP.
TABLE 1. DEMOGRAPHIC CHARACTERISTICS AND OCULAR DIMENSIONS OF PRIMARY ANGLE CLOSURE GLAUCOMA 
SUBJECTS
 
IN
 
THIS STUDY.
Characteristic
                                            Previous
 Overall                           symptomatic
 (n=108)                           PACG(n=49)
Asymptomatic
chronic PACG
(n=59) Sex
Male 31 (28.7%) 10 21
Female 77 (71.3%) 39 38
Age (years)
Mean±SD 66.2±9.1 64.2±8.8 67.8±9.0
range (46–86)
Axial length (mm)
Mean±SD 21.90±0.50 21.79±0.58 21.99±0.40
(range) (19.98–22.50)
Anterior chamber
depth (mm)
Mean±SD 2.37±0.38 2.44±0.45 2.32±0.31
(range) (1.79–3.54)
The demographic features and ocular dimensions of the 108 Chinese PACG study subjects are shown. Only patients with axial
lengths less than 22.5mm were included in the study. SD: Standard deviation.
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1315TABLE 2. CHX10   AND   MFRP   SEQUENCE   ALTERATIONS   DETECTED   AND   INVESTIGATED   IN PRIMARY   ANGLE   CLOSURE   GLAUCOMA   PATIENTS.
                                                                           Allele distribution (%) Allele
Association
(p-value)
Odds ratio
(95% CI)
Genotype distribution (%) Genotype
Association
p-value
Odds ratio
(95% CI)
Cases         Controls
n=108           n=93
Cases           Controls
n=108             n=93
CHX10   Ser157Ser
 (c.471C>T)
rs35435463
Exon 3 C 206 (0.95) 177 (0.95) 1.0000 1.05 
(0.37–2.94)
CC 99 (0.92) 84 (0.903)               0.6187 1.32+ 
(0.43–4.14)
T        10 (0.05)         9 (0.05) CT 8 (0.074)      9 (0.097)                 NA                           NA
TT 1 (0.009)      0 (0.0)                     NA                           NA
*Gly243Asp
(c.728G>A)
Exon 4 G       215 (0.995) 186 (1.00)              NA NA GG      107 (0.99) 93 (1.0)                    NA NA
A          1 (0.005)       0 (0.0) GA 1 (0.01) 0 (0.0)                     NA                           NA
AA 0 (0.0) 0 (0.0)                     NA                           NA
Pro250Pro
(c.750G>A)
Exon 4 G       215 (0.995)
 (0.85–330.62)
 180 (0.97)             0.0525                    7.14              GG       107 (0.99) 87 (0.94)                 0.0506                    7.32+ 
                                                              (0.86–341.96)
A           1 (0.005)      6 (0.03) GA 1 (0.01) 6 (0.06)                    NA                           NA
AA 0 (0.0) 0 (0.0)                      NA                           NA
Asp291Asn
(c.871G>A)
Exon 5 G        209 (0.97) 178 (0.96)           0.6073                     1.34              GG         101 (0.94) 85 (0.91)                 0.6005                     1.35+
                                                              (0.41–4.59)
A           7 (0.03) 8 (0.04) GA 7 (0.06) 8 (0.09)                   NA                           NA
AA 0 (0.0) 0 (0.0)                    NA                            NA
MFRP Arg64Arg
(c.192C>G)
Exon 3          C         196 (0.99) 177 (0.99) 1.0000 0.55
(0.01-10.74)
CC            97 (0.98)    88 (0.99)               1.0000 0.55+
(0.01-10.79)
G            2 (0.01) 1 (0.01) CG 2 (0.02) 1 (0.01)                  NA                           NA
GG 0 (0.0) 0 (0.0)                   NA                            NA
Val136Met
(c.406G>A)
rs3814762
Exon4 G         185 (0.86) 157 (0.84)            0.5725                    1.18            GG             79 (0.74) 65 (0.70)              0.6316                     1.21+
                                                             (0.62 - 2.38)
A           29 (0.14)      29 (0.16) GA 27 (0.25)      27 (0.29)              1.0000 1.21++
 (0.01-96.52)
AA 1 (0.01) 1 (0.01)               1.0000 1.00+++
(0.01-81.32)
Tyr164Tyr
(c.492C>T)
rs36015759
Exon 5 C         164 (0.77) 148 (0.80)             0.5455                     0.84           CC             64 (0.60) 58 (0.62)              1.0000                      0.9 8+ 
                                                             (0.52 - 1.85)
T           50 (0.23)     38 (0.20) CT 36 (0.34)      32 (0.35)              0.3394                      0.47++
                                                                                  (0.07-2.20)
TT 7 (0.06) 3 (0.03)              0.498                        0.49+++
(0.07- 2.36)
His180His
(c.540 C>T)
rs2510143
Exon 5 C         166 (0.82) 163 (0.88)            0.1575                      0.65           CC             69 (0.68) 72 (0.78)             0.2397                       0.65+
                                                             (0.31 - 1.33)
T           36 (0.18)       23 (0.12) CT 28 (0.28)      19 (0.20)             0.4417                       0.48++
                                                                                  (0.04-3.48)
TT 4 (0.04) 2 (0.02)             1.0000 0.74+++
(0.06–5.78)
*Arg257His
(c.770 G>A)
Exon 6 G         208 (0.99) 186 (1.0)               NA NA GG             103 (0.98) 93 (1.0)                 NA NA
A             2 (0.01) 0 (0.0) GA 2 (0.02) 0 (0.0)                  NA                             NA
AA 0 (0.0) 0 (0.0)                  NA                             NA
Leu318Leu
(c.954 G>A)
rs35885438
Exon 9 G         186 (0.98) 178 (0.96)            0.2547                        2.08        GG                 91 (0.96) 85 (0.91)              0.2473                       2.13+ 
                                                              (0.55–10.04)
A             4 (0.02) 8 (0.04) GA 4 (0.04) 8 (0.09)                 NA                             NA
AA 0 (0.0) 0 (0.0)                  NA                             NA
Allele and genotype frequencies of sequence variations within CHX10 and MFRP genes in Chinese PACG patients versus Chinese control subjects. The observed
genotype distributions did not deviate from those predicted by the Hardy–Weinberg equilibrium. Proportions of groups were compared by the Fisher’s exact test.
The criterion for statistical significance was p≤0.05. DNA changes are documented based on cDNA sequences with +1 corresponding to the A of the ATG translation
initiation codon in reference sequences NM_182894.1 (CHX10) and NM_031433.1 (MFRP). The asterisks represent Gly243Asp in CHX10 and Arg257His in MFRP
that are rare putative pathogenic variants. Exon 4 of CHX10 was screened in an additional 122 control subjects to investigate the Gly243Asp variant. The vertical
arrow (+) represents odds ratios when comparing likelihood of PACG in individuals with two copies of major allele versus one copy. Double plus (++) represents
odds ratios when comparing likelihood of PACG in individuals with two copies of the major allele versus individuals with no copies of the major allele. Triple plus
(+++) represents odds ratios when comparing likelihood of PACG in individuals with one copy of major allele versus no copies of the major allele.
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Exon Sequence change Gene
 (0.42–4.44)
(0.65 - 2.14)
(0.51–1.39)
(0.35 - 1.18)
(0.55–9.63)three to five times greater risk of developing the disorder
compared with the general population [29,30,32,34]. There
are also ethnic differences with a higher prevalence among
Inuits  (2%-8%)  and  Asians  (0.3%-1.4  %)  compared  to
Caucasians (0.1%), suggesting a genetic predisposition to the
disorder  [35].  Although  these  studies  have  suggested  a
familial risk of angle closure, the precise heritability of the
condition is largely unknown. The familial risk of PACG has
also not been determined in Asian populations in which the
prevalence of the disease is high.
Due  to  the  association  of  PACG  with  small  ocular
dimensions, we investigated the role of two genes associated
with small eyes, CHX10 and MFRP, in a cohort of 108 PACG
subjects all of whom had axial lengths less than 22.5 mm. This
cut-off  was  arbitrarily  chosen  based  on  the  results  of  a
population-based study in Singapore that found that the mean
axial  length  of  adults  aged  40  years  or  older  was
23.23±1.17  mm  [36].  Recently,  another  Singapore  study
found that the mean axial length of subjects with angle closure
was 23.02 mm compared to 23.85 mm in normal subjects
[37]. However, the results of this study indicate that CHX10
and MFRP mutations do not play a major role in the causation
of chronic PACG as most of the sequence variations found are
not thought to be disease-causing. Nevertheless, to firmly
exclude a role of these genes in PACG, a larger case-control
study may be required. We found several sequence variants in
CHX10 including two silent polymorphisms (Ser157Ser and
Pro250Pro)  and  the  missense  change,  Asp291Asn,  all  of
which were found in control subjects. In MFRP, we identified
four silent variations (Arg64Arg, Tyr164Tyr, His180His, and
Leu318Leu) and a missense variation (Val136Met), which all
appear to be common MFRP polymorphisms. Interestingly,
one PACG subject had both the Gly243Asp missense change
in CHX10 and the Arg257His variation in MFRP. However,
Arg257His is a conservative substitution and is unlikely to be
pathogenic given that in homologous sequences the histidine
residue is also seen in place of the arginine residue (Figure
2B).  The  conservation  of  the  CHX10  Gly243  residue  in
homologous  sequences  (Figure  1B)  and  the  absence  of
Gly243Asp in more that 400 normal chromosomes favor it
being a disease-causing variant rather than a polymorphism.
However, we have not been able to demonstrate segregation
of Gly243Asp with the disease in the proband’s family, mostly
due to the late onset nature of the disease. To our knowledge,
there  is  no  evidence  of  family  history  of  disease  in  the
proband’s  family.  Therefore,  in  the  absence  of  any  other
convincing  mutations  in  CHX10  for  PACG,  one  cannot
discount  the  possibility  of  Gly243Asp  still  being  a  rare
nonpathogenic variant.
PACG can also be a slowly progressive disease process
that can be accelerated by an enlarging cataractous lens from
middle age onwards. The axial lengths of patients with PACG
appear to be shorter than the normal population but not as short
as nanophthalmic eyes. It can be speculated that PACG eyes
may  form  one  end  of  the  large  spectrum  of  structural
anomalies seen in both microphthalmos and nanophthalmos,
making both CHX10 and MFRP good candidate genes for
PACG. However, our results did not support a significant role
for CHX10 or MFRP mutations in PACG.
There has been a paucity of research into the genetic basis
of PACG. To date, a genetic locus for PACG has not been
published, and there have been few other reports of candidate
gene association studies related to PACG. This is probably
related to the high prevalence of the condition in populations
where glaucoma research has not been a major focus. There
may be under-reporting of a family history as in POAG that
may lead to the impression that most affected patients are
isolated cases. The late onset of the disease and the lack of
accurate  clinical  information  on  previous  generations  are
further obstacles to determining the genetics of the disorder.
It is hoped that further research into the genetic basis of PACG
would lead to improved understanding of the molecular basis
of this major cause of world blindness.
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